Retension Pharmaceuticals CEO awarded 40,884 options

One-quarter of the options vests on August 14, 2027, with the remainder vesting monthly over 36 increments subject to continued service.

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. CEO Eric L. Keller received a direct award of options covering 40,884 shares of common stock on October 22, 2026. The options have a $15.50 exercise price and expire October 22, 2036. The award was made under the company’s 2026 Equity Incentive Plan following underwriters’ exercise of their over-allotment option in the initial public offering, pursuant to Keller’s employment letter dated August 14, 2026. Twenty-five percent vests on August 14, 2027; the remaining options vest in 36 monthly increments thereafter, subject to continued service on each vesting date.

Insider Trade Summary

Grant/Award: 40,884 shares

Grant/Award 1 txn

Insider Keller Eric L.

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	40,884	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,884 contracts (Direct)

Footnotes (1)

1. F1. Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. The option award was granted as a result of the underwriters' exercise of their over-allotment option on October 22, 2026 in connection with the Issuer's initial public offering, pursuant to the terms of the Reporting Person's Offer of Employment Letter with the Issuer, dated August 14, 2026. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Option award: 40,884 shares Exercise price: $15.50 per share Initial vesting: 25% +2 more

5 metrics

Option award 40,884 shares Awarded October 22, 2026

Exercise price $15.50 per share Option award

Initial vesting 25% Vests August 14, 2027

Remaining vesting schedule 36 monthly increments Subject to continued service on each vesting date

Option expiration October 22, 2036 Option award

Key Terms

over-allotment option, vesting, Equity Incentive Plan, initial public offering

4 terms

over-allotment option financial

"underwriters' exercise of their over-allotment option"

An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.

vesting financial

"remaining stock options vesting in 36 monthly increments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Equity Incentive Plan financial

"Issuer's 2026 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

initial public offering financial

"in connection with the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did RTSN CEO Eric L. Keller receive?

Eric L. Keller received a direct option award covering 40,884 shares of common stock on October 22, 2026. The options have a $15.50 exercise price and expire October 22, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 07:34 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keller Eric L.

(Last) (First) (Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH VIRGINIA 22046

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$15.5	10/22/2026		A		40,884		(1)	10/22/2036	Common Stock	40,884	$0	40,884	D

Explanation of Responses:

1. Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. The option award was granted as a result of the underwriters' exercise of their over-allotment option on October 22, 2026 in connection with the Issuer's initial public offering, pursuant to the terms of the Reporting Person's Offer of Employment Letter with the Issuer, dated August 14, 2026. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

	/s/ Alex Schwartz, Attorney-in-fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)